Articles

Key View

• We have revised upward our forecast for UK real GDP growth in 2024 from -0.1% to 0.5%, as the economy has had a much stronger start to the year than we previously anticipated.
• Several tailwinds will support growth throughout Q2 and into Q3 2024. This includes declining inflation, decent wage gains, as well as lower National

Key View

• Roche’s latest Columvi data will support the drug’s full approval in the US and Europe.
• Approval as an earlier line treatment will give Roche an edge over AbbVie and Genmab’s Epkinly.
• Bispecific therapies will continue to attract interest from cancer drugmakers.

Roche’s latest Columvi (glofitamab) data will support the drug’s

Key View

• We forecast that the Bank of Namibia (BoN) will begin its monetary easing cycle in Q3 2024, cutting the repo rate by 50 basis points (bps) to 7.25% by end-2024.
• The BoN will aim to safeguard the Namibian dollar’s one-to-one peg with the South African rand which will prompt it to closely follow the SARB’s monetary policy decisions

Latest Development: Reportedly, in 2021, telecom operators in the Democratic Republic of Congo (DRC) agreed to collectively pay an additional USD5.8mn per month to the telecoms regulator through to 2030, an arrangement that is allegedly still in effect but which has not been previously disclosed. Details are scarce regarding the telecoms tax

Please note: BMI is enhancing its risk analysis with a new scoring system following acquisition of GeoQuant, a market-leading provider of political risk data. From 27th March 2024, risk scores are inverted: zero now represents the lowest risk and 100 the highest, for clearer, industry-standard assessments. For further details, please refer to

Key View

• We expect Denmark's economic growth to slow marginally in 2024, projecting a GDP expansion of 1.6%, a slight decrease from the 1.9% growth rate observed in 2023.
• While monetary policy is set to become more accommodative, less favourable base effects – stemming from stronger-than-expected growth in 2023 – will temper the growth

Key View

• Roche’s latest Columvi data will support the drug’s full approval in the US and Europe.
• Approval as an earlier line treatment will give Roche an edge over AbbVie and Genmab’s Epkinly.
• Bispecific therapies will continue to attract interest from cancer drugmakers.

Roche’s latest Columvi (glofitamab) data will support the drug’s

Key View

• We expect that Botswana’s current account surplus will widen to 1.1% of GDP in 2024, from an estimated 0.4% in 2023. 
• Recovering global demand for diamonds will provide tailwinds to exports in 2024, prompting a widening of the trade surplus.
• Risks to Botswana’s external position will remain limited given robust reserves and

Key View

• For the time being, we believe that the outcome of the 2024 US presidential election remains too close to call, as we envisage a very close race between President Joe Biden and his predecessor, Donald Trump. The possibility that Trump will return to the presidency is raising concerns at home and abroad about potential shifts in US

Key View

• As we expected, the US House of Representatives approved USD95bn in foreign aid on April 20 including USD60.7bn in aid for Ukraine (31.8% of GDP).
• The resumption of US military aid should provide Ukraine with just enough materiel to defend itself, but its forces will still lack resource volumes required to contest the battlefield